Fiomi Diagnostics is develops a panel of point-of-care cardiac marker assays. The company’s forecast technology enables picomolar sensitivity for whole-blood in vitro diagnostic immunoassays at the point of care. Its technology is based on a microstructured plastic chip, which provides a highly repeatable flow of fluid in lateral flow assays and an